Introduction
============

Obstructive sleep apnea syndrome (OSAS) is a prevalent disorder, affecting 4% of adults ([@b1-mmr-13-01-0137]). Patients with OSAS manifest with repetitive episodes of transient oxygen de-saturation during sleep, resulting in progressive multisystem damage ([@b2-mmr-13-01-0137]). It has been recently reported that OSAS is an independent risk factor for a number of cerebral vascular disorders and is associated with Alzheimer\'s disease. Surgical treatment may only partially improve cognitive function in patients with OSAS. Thus, OSAS-induced damage to the brain may be irreversible ([@b3-mmr-13-01-0137],[@b4-mmr-13-01-0137]). Although the pathophysiological basis of cerebral complications in OSAS is likely to be multifactorial, including sympathetic excitation, cerebral vascular contraction, inflammation, oxidative stress and a disorder of the metabolism ([@b5-mmr-13-01-0137]--[@b8-mmr-13-01-0137]), the precise underlying mechanisms remain to be elucidated and require further investigation.

The mitogen-activated protein kinases (MAPKs) comprise a family of ubiquitous proline-directed protein-serine/threonine kinases, which are essential in the sequential transduction of biological signals from the cell membrane to the nucleus ([@b9-mmr-13-01-0137]). In mammalian cells, there are three well-defined sub-groups of MAPKs: Extracellular signal-regulated kinases (ERKs, including ERK1 and ERK2 isoforms), the c-Jun N-terminal kinases (JNKs, including JNK1, JNK2 and JNK3 isoforms), and the P38MAPKs, including P38-α, -β, -γ and -δ isoforms. Studies have demonstrated that in mammalian cells, MAPKs can be activated by a variety of stimuli, and in turn, the activated MAPKs may typically phosphorylate a number of downstream substrates, including c-Raf-1, MAPK kinase, ERK-1, and c-Fos, which regulate a number of genes involved in neuronal apoptosis, including B-cell lymphoma 2 (Bcl-2) and caspase-3 ([@b10-mmr-13-01-0137]--[@b12-mmr-13-01-0137]). Studies have demonstrated that sustained cellular hypoxia is associated with the activation of a MAPK pathway mediated by the transcription factor hypoxia-inducible factor-1, vascular endothelial growth factor and inducible nitric oxide synthase ([@b13-mmr-13-01-0137]--[@b15-mmr-13-01-0137]). These factors mediate an adaptive response to hypoxia, and are directed toward increasing tissue perfusion and oxygenation to overcome the initial hypoxic insult. It is known that intermittent episodes of hypoxia, particularly the associated episodes of intermittent re-oxygenation, are an important factor for OSAS-associated cerebral injury. Previous studies by our group have revealed that intermittent episodes of hypoxia changed the degree of JNK activation in the cortex and hippocampus in a rat model of intermittent hypoxia of differing degrees ([@b16-mmr-13-01-0137]). Additional study is required to elucidate the response of the hippocampus, a major component of the brain for memory, to hypoxia by examining the expression of key MAPKs, including ERK1/2, P38MAPK and JNK.

The present study assessed the effects of intermittent hypoxia on MAPKs and the expression of apoptotic genes in the hippocampus of a rat model, which may represent a critical mechanism for OSAS-associated brain damage in humans.

Materials and methods
=====================

Animal model of hypoxia
-----------------------

The protocol of the present study was approved by the ethics committee of North China University of Science and Technology (Tangshan, China). A total of 60 male Sprague-Dawley rats (weight, 170±10 g; age, 8 weeks; Beijing Experimental Animal Center, Chinese Academy of Science, Beijing, China) were selected as a model in the present study. The rats were housed in polycarbonate cages with compressed fiber bedding at 21--25°C and 40--60% relative humidity. Food and water were available *ad libitum* in the cage. The animals were randomly divided into three groups, consisting of control, continued hypoxia and intermittent hypoxia groups, and rats in these three groups were further assigned to 2nd, 4th, 6th and 8th week sub-groups, each including five rats. The corresponding control sub-groups contained the same quantity of rats.

The animals in the intermittent hypoxia group were kept in a hypoxia chamber with cycled changes of the hypoxic conditions (2 min) for 8 h daily between 8:00 am and 4:00 pm. The chamber was filled with nitrogen and compressed air (Gas Tech Hexagonal Co., Ltd., Tianjin, China), and in each cycle, for the first 30 sec, the oxygen concentration inside was lowered to 10% and maintained for 50 sec, followed by an increase in the oxygen concentration to 21% for 40 sec. Animals in the continued hypoxia group were kept in the hypoxia chamber, which was filled with nitrogen and compressed air and a continuously maintained oxygen concentration of 10%, for 8 h between 8:00 am and 4:00 pm. The animals in the control group were kept in the hypoxia by filed with air (21% oxygen) chamber for 8 h between 8:00 am and 4:00 pm. The change of the oxygen concentration in the chamber was measured using an oxygen monitor and the oxygen concentration was maintained within the range of required concentrations ± 0.5%. Blood (0.1 ml) was extracted from the arteria carotis using a micro-injector, a total of 12 times in one cycle (with measurements performed every 10 sec). Blood gas values were measured using a blood gas analyzer (AVL OMNI automatic blood analyzer; Roche Diagnostics, Basel, Switzerland).

Tissue preparation
------------------

A total of five rats in the control or treatment groups were decapitated under anesthesia (10% chloral hydrate; 40 mg/kg i.p). Sections of brain hippocampal tissues were separated and fixed with 4% paraformaldehyde solution for histological detection and immunohistochemical analysis. Another section of hippocampal tissue was rapidly frozen in liquid nitrogen. The frozen tissue samples were homogenized in 1:10 (w/v) ice-cold homogenization buffer A \[10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.9, 0.5 mM MgCl~2~, 10 mM KCl, 0.1 mM EDTA, 0.1 mM ethylene glycol tetraacetic acid, 50 mM NaF, 5 mM dithiothreitol, 10 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1% NP-40 and proteinase inhibitors; 1 mM each of benzamidine, bisnitrophenyl phosphate and phenylmethylsulfonyl fluoride, and 5 *µ*g/ml each of aprotinin, leupeptin and pepstatin A; Xinran Biological Technology Co. Ltd., Shanghai, China\], followed by centrifugation at 1,000 × g for 15 min at 4°C. The supernatants, as cytosolic components, were collected and the protein concentration was determined.

Histological analysis with hematoxylin and eosin (H&E) staining
---------------------------------------------------------------

Post-fixed hippocampal brain tissues were embedded in paraffin and cut into 5-*µ*m coronal sections using a microtome. Paraffin-embedded brain sections were de-paraffinized with xylene and re-hydrated using an ethanol gradient (100--70% v/v) (both from Tianjin Sheng Winton Chemical Co., Ltd., Tianjin, China), followed by washing with water. The sections were stained with 0.1% (w/v) H&E (Nanjing Aoduofuni Biotechnology Co., Ltd., Nanjing, China), and examined using light microscopy (Olympus BX53; Olympus, Tokyo, Japan). The number of surviving hippocampal CA1 pyramidal cells per 1 mm length was used to calculate the neuronal density.

Western blot analysis
---------------------

Protein samples (20 *µ*g each) were separated using 10 or 7.5% SDS-PAGE (Sigma-Aldrich, St. Louis, MO, USA) and electrotransferred onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA) according to a previously described method ([@b16-mmr-13-01-0137]). Following blocking with 3% bovine serum albumin for 3 h, the membranes were probed with the following primary antibodies: phosphorylated (p)-ERKl/2 rabbit anti-mouse polyclonal antibody (cat. no. SC7383), p-P38MAPK monoclonal antibody (cat. no. bs-547612), p-JNK (cat. no. elr-0011876) and rabbit polyclonal anti-β-actin (cat. no. 4970P) (all 1:1,000 dilution; Cell Signaling Technology, Inc., Danvers, MA, USA). Furthermore, Bcl-2 rabbit polyclonal anti-mouse antibody and Bcl-2-associated X protein (Bax) polyclonal rabbit anti-mouse antibody were used (both from Wuhan Boster Biological Engineering Co., Ltd., Wuhan, China). Membrane-bound antibodies were further detected using alkaline phosphatase-conjugated goat anti-mouse or rabbit immunoglobulin (Ig) G (1:10,000 dilution, Sigma-Aldrich). The immunoreactivity was assessed using a NBT/BCIP assay kit (Kexing Biological Technology Co., Ltd., Shanghai, China). The band densities on the membrane were measured using an image analyzer (Lab Works Software version 17.0; UVP Inc., Upland, CA, USA) and normalized to the internal control.

Immunohistochemical analysis
----------------------------

Coronal sections of the tissue samples were blocked in 5% normal goat serum and then incubated in mouse anti-rat Bax (1:250) or Bcl-2 (1:200) antibody (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) overnight at 4°C. An equivalent dilution of rat IgG was used as the primary antibody for the negative control. Subsequently, the sections were incubated in biotinylated rabbit anti-mouse secondary antibody (1:500 dilution) for 90 min at room temperature followed by incubation with an avidin-biotin complex for 90 min. Finally, the sections were developed with stable 3,3′-diaminobenzidine (DAB color kit; Wuhan Boster Biological Engineering Co., Ltd.) and the nuclei were counter-stained with hematoxylin. Brown-stained positive cells were examined microscopically. Quantitative analysis of positive cells in the hippocampal CA1 region was performed on five slices of each specimen using Motic-6.0 image acquisition and image analysis system (magnification, ×200; Motic Med 6.0 digital medical image analysis system; Beijing Aeronautics and Astronautics University, Beijing, China). The ratio of positive cells to the total cell number was calculated.

Malondialdehyde (MDA) and superoxide dismutase (SOD) analysis
-------------------------------------------------------------

The frozen hippocampal tissue samples were homogenized in PBS and centrifuged (12,000 ×g for 15 min). The MDA content and the activities of SOD were detected, respectively according to the kit specification. MDA, a lipid peroxide degradation product, was condensed with thiobarbituric acid to form a red product, which was detected at 532 nm using the MDA test kit from Jiancheng Bioengineering Co., Ltd., Nanjing, China. A standard curve was included in the experiment and the content of MDA was expressed as nmol/mg total tissue protein. SOD activity was determined using an enzyme kit (Ransod; Randox Laboratories, Inc., Crumlin, UK). The method employs xanthine and xanthine oxidase to produce superoxide radicals that react with 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride to form a red formazan dye. The SOD activity was measured photometrically by the degree of inhibition of this reaction at 550 nm at 37°C and expressed as U/mg total tissue protein. A total of 1 unit of SOD inhibits the rate of increase in absorbance at 550 nm by 50% under the conditions of the assay. The SOD activity was determined from the percentage inhibition of the test sample according to an SOD standard curve.

Statistical analysis
--------------------

All values are expressed as the mean ± standard deviation. Comparisons between groups were made using one-way analysis of variance and Newman-Keuls test. P\<0.05 was considered to indicate a statistically significant difference. SPSS 16.0 (SPSS, Inc., Chicago, IL, USA) was used for analysis.

Results
=======

Blood gas parameters
--------------------

The blood PO~2~ of rats in the control group (21% O~2~) was maintained in a range between 98 and 102 mmHg; The lowest blood oxygen PO~2~ of rats in the intermittent hypoxia group (10% O~2~) reached 48.8 mmHg. In addition, the lowest blood oxygen PO~2~ of rats in the continued hypoxia group (10% O~2~) was maintained in a range between 37.4 and 39.6 mmHg.

Intermittent hypoxia causes neuronal cell loss in the hippocampal CA1 region
----------------------------------------------------------------------------

To examine the effects of intermittent hypoxia, as observed in OSAS, on neuronal loss, H&E staining was performed to examine the survival status of CA1 pyramidal neurons ([Fig. 1](#f1-mmr-13-01-0137){ref-type="fig"}). The normal cells exhibited round-shaped and pale-stained nuclei. Shrunken cells with pyknotic nuclei following ischemia were counted as dead cells. The number of surviving neurons in the hypoxic groups were significantly lower than that in the control group (P\<0.05) ([Table I](#tI-mmr-13-01-0137){ref-type="table"}). In addition, intermittent hypoxia led to a significant neuronal degeneration and the number of surviving neurons in the intermittent hypoxia group was significantly lower than that in the continued hypoxia group (P\<0.05).

MAPK phosphorylation is increased following intermittent hypoxia
----------------------------------------------------------------

Western blot analysis revealed that levels of phosphorylated ERK1/2, P38MAPK and JNK in the continued hypoxia group were significantly higher than those in the control group (P\<0.05), and levels of phosphorylated ERK1/2 were increased from the 2nd week and reached a peak at the 4th week, then declined after hypoxia, while the levels of phosphorylated P38MAPK and JNK were gradually increased and peaked at the 8th week after hypoxia. By contrast, the levels of phosphorylated ERK1/2, P38MAPK and JNK in the intermittent hypoxia group were all markedly and constantly increased from the 2nd week to the 8th week after hypoxia. In addition, the levels of phosphorylated ERK1/2, P38MAPK and JNK in the intermittent hypoxia group were significantly higher than those in the continued hypoxia group at all time-points (P\<0.05; [Figs. 2](#f2-mmr-13-01-0137){ref-type="fig"}[](#f3-mmr-13-01-0137){ref-type="fig"}--[4](#f4-mmr-13-01-0137){ref-type="fig"}; [Tables II](#tII-mmr-13-01-0137){ref-type="table"}--[IV](#tIV-mmr-13-01-0137){ref-type="table"}).

Bax and Bcl-2 are increased following intermittent hypoxia
----------------------------------------------------------

To verify the downstream effects of MAPK activation following intermittent hypoxia in the rat model of OSAS, immunohistochemical assays were performed to identify the expression of two members of the Bcl-2 family, namely the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-2. The results revealed an increase in Bcl-2 expression at the 2nd, 4th and 6th week, but a decease at the 8th week in the continued hypoxia group in comparison to that in the control group. By contrast, Bcl-2 expression was increased at the 2nd and 4th week, but deceased at the 6th and 8th week in the intermittent hypoxia group. In addition, the levels of Bcl-2 in the intermittent hypoxia group were significantly higher than those in the continued hypoxia group at the high end of the range (33.84±8.32 at the 4th week in the intermittent hypoxia group vs. 30.96±9.66 at the 6th week in the continued hypoxia group) and at the low end of the range (9.24±2.42 the intermittent group vs. 14.36±4.46 in the continued group at the 8th week) levels ([Table V](#tV-mmr-13-01-0137){ref-type="table"} and [Fig. 5](#f5-mmr-13-01-0137){ref-type="fig"}). Bax expression in the continued hypoxia group was significantly higher than that in the control group (P\<0.05) at the 6th and 8th week, whereas its expression in the intermittent hypoxia group was increased at all experimental time-points ([Table VI](#tVI-mmr-13-01-0137){ref-type="table"} and [Fig. 6](#f6-mmr-13-01-0137){ref-type="fig"}). The Bcl-2/Bax ratio was markedly lower in the intermittent hypoxia group than that in the continued hypoxia group (P\<0.05; [Table VII](#tVII-mmr-13-01-0137){ref-type="table"}.

Analysis of MDA and SOD activity
--------------------------------

To further identify the association between oxidative stress and MAPK activation, changes in MDA, a lipid metabolic product in the oxidative reaction, and SOD, an important anti-oxidant, in the experimental hypoxia groups. The results demonstrated that the MDA content increased in the two hypoxia groups and was significantly elevated compared to that in the control (P\<0.05). The MDA content reached a peak level at the 6th and the 8th week, respectively, in the continued and the intermittent hypoxia groups. Of note, the MDA content in the intermittent hypoxia group was significantly higher than that in the continued hypoxia group at each time-point (P\<0.05) ([Table VIII](#tVIII-mmr-13-01-0137){ref-type="table"}). The SOD activity was decreased and reached its lowest level at the 6th week in the two hypoxia groups and this low level of SOD persisted until the 8th week of the experiments. In addition, the SOD activity in the intermittent hypoxia group was consistently lower than that in the continued hypoxia group ([Table IX](#tIX-mmr-13-01-0137){ref-type="table"}).

Discussion
==========

OSAS is widely recognized as an independent risk factor for cerebrovascular diseases, particularly cerebral stroke. It increases the incidence of cerebral stroke by two times even after adjustment for potential confounding factors ([@b15-mmr-13-01-0137]). In addition, the majority of patients with OSAS exhibit symptoms of nervous system damage, manifested as a dysfunction in learning, memory and decision-making ability ([@b17-mmr-13-01-0137]). Mitchell *et al* ([@b18-mmr-13-01-0137]) reported that cognitive function in patients with OSAS was only partially improved, even following surgical treatment. Furthermore, it is associated with changes in brain structure, including a reduction in the gray matter in the hippocampus, frontal cortex, anterior cingulate cortex and other sections as well as volume atrophy ([@b19-mmr-13-01-0137]--[@b20-mmr-13-01-0137]). A previous study by our group demonstrated that various degrees of intermittent hypoxia induced injury to the neural cell ultrastructure as well as nerve cell loss, which were irreversible ([@b21-mmr-13-01-0137]). In the present study, it was illustrated that intermittent hypoxia elicited a severe level of neuronal degeneration and neuronal death in comparison to continued hypoxia in a rat model, suggesting that intermittent hypoxia in OSAS may induce marked damage to nerve cells.

The MAPK pathway is activated in the brains of animal models of cerebral ischemia; furthermore, it has been demonstrated that the MAPK signaling pathway is important in cerebral ischemia/reperfusion, the closed head injury model and perinatal hypoxia-ischemia ([@b22-mmr-13-01-0137]--[@b24-mmr-13-01-0137]). Further studies have also assessed the timing and location of the MAPK activation in various brain tissues under different stress conditions. Guo *et al* ([@b25-mmr-13-01-0137]) proposed that ERK1/2 activity, instead of JNK1/2 activity, was increased 30 min after cerebral ischemia in a model of permanent forebrain ischemia in rats induced using the four artery ligation method. In a cerebral ischemia-re-perfusion model, the ERK1/2 activity began to increase at 15 min and peaked at 6 h, while JNK1/2 activity increased after 1 h and gradually increased to peak at 21 h; both activated ERKl/2 and JNKl/2 were detected at 24 h after injury. It is noteworthy that activated ERKl/2 instead of JNKl/2 was also induced by another re-perfusion ([@b26-mmr-13-01-0137]). In a gerbil model of brain ischemia-re-perfusion induced by bilateral common carotid artery blocking, indications of MAPK activation, including ERKl/2 phosphorylation, mainly existed in the CA3/dentate gyrus sub-region at a short time after ischemia and was lowly expressed in the CA1 sub-region. With the extension of ischemia, JNKl/2 and P38MAPK phosphorylation levels were increased in the CA1 and CA3 sub-regions ([@b27-mmr-13-01-0137]). In the present study, western blot analysis indicated that in the continued hypoxia model, phospho-ERKl/2 was markedly increased at various time-points and reached a peak level at four weeks, after which it declined. With increasing time following hypoxia, active P38MAPK and JNKl/2 were detected. In the intermittent hypoxia group, phospho-ERKl/2, P38MAPK and JNKl/2 increased markedly from two weeks after hypoxia, and ERK1/2 activity maintained a stable increase to the top level from the 2nd to the 8th week in the experimental period. Activated P38MAPK and JNKl/2 were gradually increased, reaching their highest levels at the 8th week also. The results of the present study suggested that the MAPK signaling pathways were selectively activated under various hypoxic conditions. It is possible that intermittent hypoxia induced by OSAS activated MAPK signaling pathways in a continually excessive manner. It is known that P38MAPK and JNK are similar in nature, and the activation of either has a negative regulatory role, leading to cell injury and death ([@b11-mmr-13-01-0137],[@b12-mmr-13-01-0137],[@b28-mmr-13-01-0137]). By contrast, ERKl/2 has a dual effect, which may promote cell survival and proliferation with appropriate activation in the short term, but may also cause cell death with excessive activation in the long term ([@b29-mmr-13-01-0137],[@b30-mmr-13-01-0137]). Alessandrini *et al* ([@b31-mmr-13-01-0137]) demonstrated that ERK1/2 phosphorylation and cytochrome C were increased following cerebral injury, and co-localized within the same nerve cell. The activation of ERK1/2 may upregulate the protective anti-oxidant system and promote neuronal survival ([@b32-mmr-13-01-0137]). The Ras/ERK1/2 cascade has been hypothesized to be a tolerance core of neurons in cerebral ischemic stress ([@b33-mmr-13-01-0137]). In fact, MAPK activation in mammalian cells has coordinating effects and the same simulation is able to activate various MAPK pathways. For example, stress reactions are able to activate the ERKl/2, P38MAPK and JNK1/2 pathways ([@b34-mmr-13-01-0137]), while epidermal growth factor may stimulate ERKl/2 and JNKl/2 signals ([@b35-mmr-13-01-0137]). In addition, activated MAPKs may phosphorylate or activate the same transcription factor, such as ERK-1, and thus integrate extracellular stimuli, ultimately leading to biological reactions to induce cell survival or death ([@b36-mmr-13-01-0137]).

In the present study, certain correlations between activated ERKl/2 and the expression of Bcl-2 family members were identified. The levels of Bcl-2 and ERK1/2 began to increase at the 2nd week and reached a peak at the 4th week or the 6th week, and then decreased in the continued hypoxia group. Bax expression gradually increased and reached a peak at the 8th week in association with a decrease in phospho-ERKl/2 and increases in activated P38MAPK and JNKl/2 in the continued hypoxia group. In the intermittent hypoxia group, activated ERKl/2 maintained a steady increase reaching the top level at the 8th week; however, Bcl-2 expression reached a peak at 4 weeks and then gradually decreased. It is well established that Bcl-2 and Bax exhibit the opposite biological functions. Bcl-2 is able to enhance cell survival following ischemia and hypoxia by maintaining mitochondrial membrane integrity, whereas Bax promotes ischemia or hypoxia-induced cell death via the release of cytochrome C. Thus, the ratio of Bcl-2 to Bax affects the survival of cells ([@b37-mmr-13-01-0137],[@b38-mmr-13-01-0137]). Based on changes in the ratio of Bcl-2 to Bax and MAPK signaling pathway activation under various hypoxic conditions, the present study hypothesized that in the continued hypoxia group, ERKl/2 activation may have had a protective effect and enhanced Bcl-2 expression. This may have increased the compensatory function of nerve cells resistant to low oxygen. However, the intermittent hypoxia of OSAS may resemble re-perfusion injury, resulting in a marked stress reaction and continued, excessive activation of the MAPK signaling pathways. The possible role of ERKl/2 activation at the early stages may have increased the tolerance to hypoxia for a short period. However, with prolonged intermittent hypoxia, the MAPK signaling pathway was excessively activated, leading to abnormal expression of Bcl-2 and Bax and the death of nerve cells. This may be an important molecular mechanism for OSAS-associated injury to the brain.

In the animal model, hypoxia enhanced the production of MDA and reduced the activity of SOD in a time-dependent manner, particularly in the intermittent hypoxia group. Hypoxia has been reported to result in a marked elevation in reactive oxygen species (ROS) in non-brain tissues ([@b39-mmr-13-01-0137]). The present study illustrated differences in the type and extent hypoxia on MAPK activation, including increases of MDA or decreases of SOD, suggesting an association between changes in the oxidative stress reaction and MAPK activation in the pathological process of nerve injury induced by hypoxia. Direct exposure of cells to exogenous H~2~O~2~, to mimic oxidative stress, leads to the activation of MAPKs ([@b40-mmr-13-01-0137]). The prevention of ROS accumulation by anti-oxidants blocks MAPK activation in cells exposed to specific stimuli ([@b41-mmr-13-01-0137],[@b42-mmr-13-01-0137]). A previous study by our group reported that oxidative stress initiated the JNK pathway, which mediated nerve cell injury in a model of severe intermittent hypoxia ([@b41-mmr-13-01-0137]). ROS may trigger the ERK1/2 pathway through activation of growth factor receptors ([@b43-mmr-13-01-0137]) or modification of apoptosis signal-regulating kinase 1, a member of the MAP3K superfamily, which targets JNK and P38MAPK. In addition, ROS oxidize the cysteine residues in MAPK phosphatase, leading to activation of the JNK and P38 pathways. Under the conditions of intermittent hypoxia found in OSAS, oxidative reactions due to marked repetitive re-oxygenation enhance the early damage of nerve cells.

In conclusion, the present animal study indicated that MAPK signaling pathways were selectively activated in the hippocampus under intermittent and continued hypoxic conditions. In addition, excessive activation of MAPK signaling pathways by intermittent hypoxia elicited abnormal expression of Bcl-2 and Bax as well as a severe loss of hippocampal nerve cells. This phenomenon was also closely associated with oxidative stress, inducing an elevated production of MDA and the downregulation of SOD. These findings suggested a critical role of MAPK activation in OSAS-induced brain pathogenesis, and provided therapeutic strategies for the prevention and treatment of this common disease.
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![Representative photomicrographs of hematoxylin and eosin-stained sections of hippocampi at the 6th and 8th week after hypoxia (magnification, ×400). (A) In the control group, normal cells exhibited round-shaped and pale-stained nuclei. (B and C) Dead cells exhibited a shrunken cytoplasm with pyknotic nuclei in the continued hypoxia group at (B) the 6th week and (C) the 8th week following hypoxia. (D and E) Increased numbers of dead cells in the intermittent hypoxia group at (D) the 6th week and (E) the 8th week following hypoxia.](MMR-13-01-0137-g00){#f1-mmr-13-01-0137}

![Western blots of phospho-ERK1/2 expression in hippocampal regions. (A) Control group; (B) continued hypoxia group; (C) intermittent hypoxia group. p-ERK, phosphorylated extracellular signal-regulated kinase; w, weeks.](MMR-13-01-0137-g01){#f2-mmr-13-01-0137}

![Western blots of phospho-P38MAPK expression in hippocampal regions. (A) Control group; (B) continued hypoxia group; (C) intermittent hypoxia group. MAPK, mitogen-activated protein kinase.](MMR-13-01-0137-g02){#f3-mmr-13-01-0137}

![Western blots of phospho-JNK expression in hippocampal regions. (A) control group; (B) continued hypoxia group; (C) intermittent hypoxia group. JNK, c-Jun N-terminal kinase.](MMR-13-01-0137-g03){#f4-mmr-13-01-0137}

![Bcl-2-positive cells revealed by immunohistochemistry in the hippocampus following hypoxia (magnification, ×400). (A) Few Bcl-2-positive cells in the control group; (B) Numerous Bcl-2-positive cells with brown-staining at the 6th week, and (C) decreased number of positive cells at the 8th week in the continued hypoxia group; (D) Numerous Bcl-2 positive cells at the 2nd week and (E) decreased number of positive cells at the 6th week in the intermittent hypoxia group. Bcl-2, B cell lymphoma-2.](MMR-13-01-0137-g04){#f5-mmr-13-01-0137}

![Bax-positive cells were detected using immunohistochemistry in the hippocampus after hypoxia (magnification, ×400). (A) Few Bax-positive cells in the control group. (B) Numerous Bax-positive cells with brown staining at the 6th week in continued hypoxia. (C) The number of Bax-positive cells was maximal at the 8th week in continued hypoxia; (D) Bax-positive cells at the 2nd week and (E) at the 8th week in the intermittent hypoxia group. Bax, Bcl-2-associated X protein.](MMR-13-01-0137-g05){#f6-mmr-13-01-0137}

###### 

Rate of surviving nerve cells in the hippocampal CA1 region of rats in various groups (% of total cells counted).

  Group          Rate of survival of nerve cells (%)                                                                                                                                                                                                                                                                                              
  -------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Control        99.4±06                                                                                                    99.3±0.7                                                                                                   99.5±0.5                                                                                                   99.4±0.6
  Continued      98.4±5.6                                                                                                   91.6±10.8[a](#tfn1-mmr-13-01-0137){ref-type="table-fn"}                                                    87.2±19.6[a](#tfn1-mmr-13-01-0137){ref-type="table-fn"}                                                    84.5±22.7[a](#tfn1-mmr-13-01-0137){ref-type="table-fn"}
  Intermittent   91.50±16.48[a](#tfn1-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn2-mmr-13-01-0137){ref-type="table-fn"}   82.75±15.80[a](#tfn1-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn2-mmr-13-01-0137){ref-type="table-fn"}   74.75±24.70[a](#tfn1-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn2-mmr-13-01-0137){ref-type="table-fn"}   70.70±26.10[a](#tfn1-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn2-mmr-13-01-0137){ref-type="table-fn"}

P\<0.05 vs. control

P\<0.05 vs. continued. Values are expressed as the mean ± standard deviation from five rats in each subgroup. Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group.

###### 

Phospho-ERK1/2 expression in the hippocampal regions of rats in various groups.

  Group          Phospho-ERK1/2 expression (band densities)                                                                                                                                                                                                                                                                                 
  -------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Control        0.52±0.15                                                                                                0.48±0.12                                                                                                0.64±0.18                                                                                                0.44±0.18
  Continued      2.49±0.96~a~                                                                                             5.84±1.17[a](#tfn3-mmr-13-01-0137){ref-type="table-fn"}                                                  3.58±1.02[a](#tfn3-mmr-13-01-0137){ref-type="table-fn"}                                                  1.96±0.82[a](#tfn3-mmr-13-01-0137){ref-type="table-fn"}
  Intermittent   4.68±1.56[a](#tfn3-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn4-mmr-13-01-0137){ref-type="table-fn"}   6.10±1.12[a](#tfn3-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn4-mmr-13-01-0137){ref-type="table-fn"}   7.86±1.56[a](#tfn3-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn4-mmr-13-01-0137){ref-type="table-fn"}   9.78±3.41[a](#tfn3-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn4-mmr-13-01-0137){ref-type="table-fn"}

P\<0.05 vs. the control group

P\<0.05 vs. the continued group. Values are expressed as the mean ± standard deviation from five rats in each subgroup. Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group; ERK, extracellular signal-regulated kinase.

###### 

Phopho-P38MAPK expression in the hippocampal regions of rats in various groups.

  Group          Phospho-P38MAPK expression (band densities)                                                                                                                                                                                                                                                                                
  -------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Control        0.60±0.17                                                                                                0.62±0.18                                                                                                0.68±0.22                                                                                                0.48±0.12
  Continued      1.17±0.24                                                                                                1.18±0.20[a](#tfn5-mmr-13-01-0137){ref-type="table-fn"}                                                  2.49±0.96[a](#tfn5-mmr-13-01-0137){ref-type="table-fn"}                                                  3.12±0.23[a](#tfn5-mmr-13-01-0137){ref-type="table-fn"}
  Intermittent   2.96±0.32[a](#tfn5-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn6-mmr-13-01-0137){ref-type="table-fn"}   3.40±0.42[a](#tfn5-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn6-mmr-13-01-0137){ref-type="table-fn"}   4.98±0.56[a](#tfn5-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn6-mmr-13-01-0137){ref-type="table-fn"}   6.84±1.01[a](#tfn5-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn6-mmr-13-01-0137){ref-type="table-fn"}

P\<0.05 vs. the control group

P\<0.05 vs. the continued group. Values are expressed as the mean ± standard deviation from five rats in each subgroup. Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group; MAPK, mitogen-activated protein kinase.

###### 

Phospho-JNK expression in the hippocampal regions of rats in various groups.

  Group          Phospho-JNK expression (band densities)                                                                                                                                                                                                                                                                                    
  -------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Control        0.68±0.22                                                                                                0.64±0.20                                                                                                0.66±0.20                                                                                                0.68±0.24
  Continued      1.12±0.28[a](#tfn7-mmr-13-01-0137){ref-type="table-fn"}                                                  1.18±0.26[a](#tfn7-mmr-13-01-0137){ref-type="table-fn"}                                                  3.40±0.42[a](#tfn7-mmr-13-01-0137){ref-type="table-fn"}                                                  4.98±0.56[a](#tfn7-mmr-13-01-0137){ref-type="table-fn"}
  Intermittent   1.82±0.25[a](#tfn7-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn8-mmr-13-01-0137){ref-type="table-fn"}   3.07±0.19[a](#tfn7-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn8-mmr-13-01-0137){ref-type="table-fn"}   4.75±0.32[a](#tfn7-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn8-mmr-13-01-0137){ref-type="table-fn"}   8.72±1.40[a](#tfn7-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn8-mmr-13-01-0137){ref-type="table-fn"}

P\<0.05 vs. the control group

P\<0.05 vs. the continued group. Values are expressed as the mean ± standard deviation from five rats in each subgroup. Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group; JNK, c-Jun N-terminal kinase.

###### 

Rate of Bcl-2-positive cells in the hippocampal CA1 region of rats in response to hypoxia.

  Group          Rate of Bcl-2-positive cells (%)                                                                                                                                                                                                                                                                                                 
  -------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Control        5.56±1.10                                                                                                  5.58±1.12                                                                                                  5.52±1.11                                                                                                  5.28±1.10
  Continued      16.54±3.96[a](#tfn9-mmr-13-01-0137){ref-type="table-fn"}                                                   24.64±5.74[a](#tfn9-mmr-13-01-0137){ref-type="table-fn"}                                                   30.96±8.32[a](#tfn9-mmr-13-01-0137){ref-type="table-fn"}                                                   14.36±4.60[a](#tfn9-mmr-13-01-0137){ref-type="table-fn"}
  Intermittent   24.86±6.38[a](#tfn9-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn10-mmr-13-01-0137){ref-type="table-fn"}   33.84±9.66[a](#tfn9-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn10-mmr-13-01-0137){ref-type="table-fn"}   20.78±5.36[a](#tfn9-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn10-mmr-13-01-0137){ref-type="table-fn"}   9.24±2.42[a](#tfn9-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn10-mmr-13-01-0137){ref-type="table-fn"}

P\<0.05 vs. the control group

P\<0.05 vs. the continued group. Values are expressed as the mean ± standard deviation from five rats in each subgroup. Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group; Bcl-2, B-cell lymphoma-2.

###### 

Rate of Bax-positive cells in the hippocampal CA1 region of rats in response to hypoxia.

  Group          Rate of Bax-positive cells                                                                                                                                                                                                                                                                                                          
  -------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Control        2.78±0.82                                                                                                   2.66±0.76                                                                                                   2.64±0.78                                                                                                   2.70±0.82
  Continued      4.14±1.56                                                                                                   4.08±1.64                                                                                                   9.72±2.80[a](#tfn11-mmr-13-01-0137){ref-type="table-fn"}                                                    22.68±6.94[a](#tfn11-mmr-13-01-0137){ref-type="table-fn"}
  Intermittent   11.44±3.24[a](#tfn11-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn12-mmr-13-01-0137){ref-type="table-fn"}   18.80±4.60[a](#tfn11-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn12-mmr-13-01-0137){ref-type="table-fn"}   26.64±8.26[a](#tfn11-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn12-mmr-13-01-0137){ref-type="table-fn"}   32.72±9.24[a](#tfn11-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn12-mmr-13-01-0137){ref-type="table-fn"}

P\<0.05 vs. the control group

P\<0.05 vs. the continued group. Values are expressed as the mean ± standard deviation from five rats in each subgroup. Bax, B-cell lymphoma-2-associated X protein. Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group.

###### 

Ratio of Bcl-2/Bax-positive cells in the hippocampal CA1 region of rats in response to hypoxia.

  Group          Rate of positive cells (fold)               
  -------------- ------------------------------- ----- ----- -----
  Control        2.0                             2.1   2.1   2.0
  Continued      4.0                             6.0   3.2   0.6
  Intermittent   2.2                             1.8   0.8   0.8

Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X protein.

###### 

Quantitative analysis of the malondialdehyde content in the hippocampal CA1 region of rats in response to hypoxia.

  Group          Malondialdehyde content (nM/mg total tissue protein)                                                                                                                                                                                                                                                                                
  -------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Control        7.60±1.47                                                                                                   7.58±1.48                                                                                                   7.58±1.46                                                                                                   7.62±1.50
  Continued      9.70±1.83[a](#tfn14-mmr-13-01-0137){ref-type="table-fn"}                                                    12.70±4.86[a](#tfn14-mmr-13-01-0137){ref-type="table-fn"}                                                   27.94±7.54[a](#tfn14-mmr-13-01-0137){ref-type="table-fn"}                                                   22.42±8.94[a](#tfn14-mmr-13-01-0137){ref-type="table-fn"}
  Intermittent   14.38±3.36[a](#tfn14-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn15-mmr-13-01-0137){ref-type="table-fn"}   18.82±5.58[a](#tfn14-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn15-mmr-13-01-0137){ref-type="table-fn"}   34.96±9.32[a](#tfn14-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn15-mmr-13-01-0137){ref-type="table-fn"}   39.92±11.28[a](#tfn14-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn15-mmr-13-01-0137){ref-type="table-fn"}

P\<0.05, vs. the control group

P\<0.05, vs. the continued hypoxia group. Values are expressed as the mean ± standard deviation from five rats in each subgroup. Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group.

###### 

Quantitative analysis of superoxide dismutase activity in the hippocampal CA1 region of rats in response to hypoxia.

  Groups         Superoxide dismutase activity (U/mg total tissue protein)                                                                                                                                                                                                                                                                           
  -------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Control        87.68±2.32                                                                                                  87.70±2.38                                                                                                  87.66±2.30                                                                                                  87.70±2.36
  Continued      76.68±2.68[a](#tfn16-mmr-13-01-0137){ref-type="table-fn"}                                                   68.50±2.62[a](#tfn16-mmr-13-01-0137){ref-type="table-fn"}                                                   60.94±2.54[a](#tfn16-mmr-13-01-0137){ref-type="table-fn"}                                                   67.42±2.94[a](#tfn16-mmr-13-01-0137){ref-type="table-fn"}
  Intermittent   68.62±2.66[a](#tfn16-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn17-mmr-13-01-0137){ref-type="table-fn"}   60.82±2.58[a](#tfn16-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn17-mmr-13-01-0137){ref-type="table-fn"}   54.96±2.32[a](#tfn16-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn17-mmr-13-01-0137){ref-type="table-fn"}   55.92±3.08[a](#tfn16-mmr-13-01-0137){ref-type="table-fn"},[b](#tfn17-mmr-13-01-0137){ref-type="table-fn"}

P\<0.05, vs. the control group

P\<0.05, vs. the continued hypoxia group. Values are expressed as the mean ± standard deviation from five rats in each subgroup. Control, control group; continued, continued hypoxia group; intermittent, intermittent hypoxia group.
